EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
Read More
Tag: SLE
Immugenyx and Janssen to develop humanised mouse model of lupus
UK biopharma Hemogenyx Pharmaceuticals has signed a deal with Janssen Research & Development to create a humanised mouse model of lupus.
Read More
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
Read More
AZ’ lupus therapy fails to hit the mark
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.
Read More
Lilly to progress Olumiant into PhIII for lupus
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
Read More
Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
Read More
GSK trials Benlysta/rituximab combo for lupus
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
Read More
GSK confirms departure of R&D chief
Ending days of speculation GlaxoSmithKline has now confirmed the departure of its current R&D chief Patrick Vallance. The drugs giant has also presented new data for lupus drug Benlysta.
Read More
GSK’s Benlysta shows sustained disease control in study
Adding GSK’s Benlysta to standard of care in patients with lupus prolonged control of disease activity, according to newly-released findings of a 10-year continuation study.
Read More
Three new medicines cleared for use by NHS Scotland
The Scottish Medicines Consortium has endorsed three medicines for routine use by NHS Scotland, offering new options to treat a rare eye disease, lupus and infertility.
Read More
GSK files for approval of subcutaneous lupus drug
GlaxoSmithKline has filed for approval of a subcutaneous formulation of its lupus drug Benlysta on both sides of the Atlantic.
Read More
Final NICE nod for GSK’s lupus drug Benlysta
Within the next three months patients with lupus should get ‘routine’ access to a new treatment option on the NHS in England and Wales after cost regulators issued final guidance for GlaxoSmithKline’s Benlysta.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
